Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Gain in-depth knowledge on oral selective estrogen receptor degrader (SERD) therapy and strategies for integrating SERDs for HR+/HER2- breast cancer cases in your clinical practice through an on-demand webcast, downloadable slides, and a podcast.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly